| |
Mergers and acquisitions are common in clinical research, requiring flexibility and agility. When a sponsor changed mid-trial, Premier seamlessly maintained regulatory compliance, patient safety, and data integrity.
Learn how in our case study.
|
|
Today’s Big NewsNov 6, 2024 |
| By James Waldron Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. |
|
|
|
By Gabrielle Masson Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or refractory multiple myeloma. After seeing the data, analysts underscored the therapy’s best-in-class potential compared to Johnson & Johnson and Legend Biotech's FDA-approved treatment Carvykti. |
By Zoey Becker Over his first term, Donald Trump advocated for lower drug prices and pharmacy benefit manager reform. Now with the Inflation Reduction Act in play, what's to come for pharma under a Trump administration? |
Sponsored by Dell Technologies While artificial intelligence is on everyone’s minds and in many R&D plans, adoption of generative AI has been slow so far in life sciences. |
|
Create an optimal path to the clinic that best suits your molecule and critical milestones. We now offer a full suite of integrated drug substance/drug product DNA-to-IND programs to accelerate any molecule type to the clinic. Download our white papers to learn more about our tailored CMC strategies.
|
|
By Nick Paul Taylor MacroGenics has pumped the brakes on vobra duo, pausing investment in additional opportunities for the antibody-drug conjugate until it has updated data from a phase 2 monotherapy prostate cancer trial. |
By Nick Paul Taylor Tango Therapeutics has shuffled TNG908 off the dance floor, halting enrollment in a study of the cancer drug candidate to focus its resources on two other molecules that hit the same target. Shares in Tango fell 26% to $3.81 in premarket trading. |
By Darren Incorvaia Ring Therapeutics is calling on Singaporean research agencies to dial into a new collaboration to develop gene therapies for eye diseases and cancer. |
By James Waldron Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher—although the biotech will only be able to keep two-thirds of the windfall. |
By Darren Incorvaia Medidata has debuted two new bundled services meant to speed up and support clinical trials in oncology and vaccines, the company announced Oct. 31. |
By Angus Liu AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy. |
|
|---|
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
